What is the Purpose of this Study?
Primary objective is to evaluate the safety and tolerability of efgartigimod PH20 SC in kidney transplant recipients diagnosed with AMR.
Eligibility
- * The participant is within the ages of 18 and 80 years old
- * The participant had a kidney transplant (living or deceased donor) at least 6 months before the study
- * The participant has received a diagnosis of active or chronic active antibody-mediated rejection (AMR) with detectable donor-specific antibodies at time of the study
- * A participant may be allowed into the study if they receive the following medications:
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod in Kidney Transplant Recipients With Antibody-Mediated Rejection